- Lobbying
- cell AND therapeutics
Lobbying Arrangements Results for 'Cell Therapeutics'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details Sickle Cell Disease Education and Advocacy. |
GLOBAL BLOOD THERAPEUTICS
|
in-house lobbying | |||
Details Reimbursements for cell and gene therapies. |
CRISPR Therapeutics, INC.
|
Capitol Counsel, LLC | |||
Details Prepare application for tax credit/grant available under Sec. 48Dof IRS code. Contacted US FDA & IRS on behalf of the client tax credit application. Determined the status of application. |
CELL THERAPEUTICS, INC.
|
HOLLAND & KNIGHT LLP | |||
Details Education about access to innovative sickle cell disease therapies and proposed legislation to increase funding and care coordination for patients with sickle cell disease. |
Global Blood Therapeutics
|
W Strategies, LLC | |||
Details Seeking support to help GBT develop and deliver life-changing treatments for people living with grievous blood-based disorders, starting with sickle cell disease. |
Global Blood Therapeutics, Inc.
|
Blue Star Strategies LLC | |||
Details Advocated for funding to advance from basic research to clinical readiness a first generation stem cell medicine for muscle regeneration and traumatic brain injury by using the fundamental biologic... |
Fate Therapeutics, Inc.
|
PETRIZZO BOND, INC. | |||
Details General issues related to access for cell and gene therapies (no specific bills). General issues related to reimbursement and FDA regulatory pathways for cell and gene therapies (no specific bills)... |
CRISPR THERAPEUTICS, INC.
|
in-house lobbying | |||
Details Issues pertaining to cell and gene therapies, and sickle cell disease. |
CRISPR THERAPEUTICS INC.
|
Empire Consulting Group | |||
Details Healthcare policy and appropriations issues, Sickle Cell Disease |
Global Blood Therapeutics, Inc.
|
Olsson, Frank, Weeda, Terman & Matz, PC | |||
Details H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022. |
Global Blood Therapeutics
|
NVG, LLC | |||
Details Medicare Coverage and payment for biologics - HR 6331 |
Cell Therapeutics, Inc.
cancer treatment and pharmaceuticals |
FOLEY HOAG LLP | |||
Details Education of Massachusetts Congressional delegation offices regarding company and pending grant applications. |
Pervasis Therapeutics
|
K&L GATES LLP | |||
Details Oppose changes to Medicare reimbursement for testing done with live tissue from biopsies |
Coalition for Living Cancer Cell Treatment Testing (Oncotech* and Precision Therapeutics**)
Develop and conduct chemoresponse tests to adi oncologists in the selection of chemotherapy agents |
HEIDEPRIEM & MAGER INC | |||
Details Lobby for federal funding to support adult stem cell research and cellular therapies. Lobby with respect to S.2754, the Alternative Pluripotent Stem Cell Therapies Enhancement Act. |
PRIMECELL THERAPEUTICS LLC (FORMERLY LISTED AS PRIMEGEN BIOTECH LLC)
Biotechnology company |
KIRKPATRICK & LOCKHART PRESTON GATES ELLIS LLP (K&L GATES) | |||
Details General issues related to access for cell and gene therapies. General issues related to reimbursement and FDA regulatory pathways for cell and gene therapies. Policies related to the reauthorizati... |
CRISPR THERAPEUTICS, INC.
|
Todd Strategy Group | |||
Details Issues related to prescription drug development. |
CELL THERAPEUTICS
|
Denny Miller Associates | |||
Details no specific bills Sickle Cell Anemia education and research advocacy |
GlycoMimetics, Inc.
|
TARPLIN, DOWNS & YOUNG, LLC | |||
Details Policy issues related to access to innovative therapies, particularly focused on sickle cell disease |
Global Blood Therapeutics
|
KING & SPALDING LLP | |||
Details Issues related to access to rare disease therapies Issues related to FDA modernization and rare disease drug development Issues related to the Accelerated Approval Program Issues related to Public ... |
PTC THERAPEUTICS, INC.
|
in-house lobbying | |||
Details Patient access to rare and orphan disease therapeutics; FDA regulatory pathways for pharmaceuticals; Awareness of Cystic Fibrosis and Sickle Cell Disease; Education about non-opioid pain therapies ... |
Vertex Pharmaceuticals Incorporated
|
STANTON PARK GROUP | |||
Details Department of Defense Appropriations FY 09; Energy and Water Development Appropriations FY09; Seek appropriations for developement and testing of nanotechnology enabled defense research and nanotec... |
KIRKPATRICK LOCKHART PRESTON GATES ELLIS LLP
|
MONUMENT POLICY GROUP, LLC | |||
Details Issues related to COVID-19 and issues related to the reimbursement of self-administered drugs. Issues related to CAR-T cell therapy access and reimbursement. Monitored drug pricing issues related t... |
BRISTOL-MYERS SQUIBB COMPANY
|
THE NICKLES GROUP, LLC | |||
Details FDA and Pediatric Rare Disease Voucher Review Program. Cures and Innovation; Sickle Cell. FDA and Pediatric Rare Disease Voucher Program. |
Connect 4 Strategies, LLC (on behalf of Mast Therapeutics, Inc.)
Healthcare consulting |
Mehlman Castagnetti Rosen & Thomas, Inc. |